CPHD
CEPHEIDNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Sep. 6, 7:05 AM
    • Danaher (NYSE:DHR) inks a deal with Cepheid (NASDAQ:CPHD) to acquire all the outstanding stock of the molecular diagnostics firm for $53 a share in cash (~$4B including debt less acquired cash). The transaction should close in Q4.
    • Danaher is a conglomerate of over 20 businesses that are managed under the auspices of the Danaher Business System. Its Life Sciences & Diagnostics segment includes Beckman Coulter, HemoCure, Leica Biosystems, Leica Microsystems, Molecular Devices, Pall, Radiometer and SCIEX.
    • CPHD is up 53% premarket on light volume.
    | Tue, Sep. 6, 7:05 AM
  • Oct. 1, 2014, 5:17 PM
    • Cepheid (CPHD -1.2%) acquires the 200-odd small hospital customer relationships from its GeneXpert distributor the Laboratory Supply Company (LABSCO) for $21M and terminates their distribution agreement. The company now plans to sell direct in this segment.
    | Oct. 1, 2014, 5:17 PM